Oyster Therapeutics
Oyster Therapeutics develops protein-degrader medicines for neurodegenerative diseases.
$60MSeries A-2
ParticipantActivity from announced rounds
CE-Ventures is the venture investment brand named in Think Bioscience and Aptadir financing coverage.
Think Bioscience develops small-molecule drugs for difficult targets. Aptadir develops RNA therapeutics intended to restore expression of silenced genes. Their retained announcements establish the two investment relationships without substituting a parent corporation or an unnamed individual fund.
Oyster Therapeutics develops protein-degrader medicines for neurodegenerative diseases.
RNA therapeutics designed to restore expression of silenced genes
Develops small molecule drugs for historically challenging drug targets